HK1164168A1 - 白蛋白-澱粉樣肽的共軛物和其用途 - Google Patents

白蛋白-澱粉樣肽的共軛物和其用途

Info

Publication number
HK1164168A1
HK1164168A1 HK12105162.7A HK12105162A HK1164168A1 HK 1164168 A1 HK1164168 A1 HK 1164168A1 HK 12105162 A HK12105162 A HK 12105162A HK 1164168 A1 HK1164168 A1 HK 1164168A1
Authority
HK
Hong Kong
Prior art keywords
albumin
amyloid peptide
peptide conjugates
conjugates
amyloid
Prior art date
Application number
HK12105162.7A
Other languages
English (en)
Inventor
Barrio J Manuel Sarasa
Original Assignee
Aracln Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aracln Biotech S L filed Critical Aracln Biotech S L
Publication of HK1164168A1 publication Critical patent/HK1164168A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12105162.7A 2009-05-26 2012-05-25 白蛋白-澱粉樣肽的共軛物和其用途 HK1164168A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382078A EP2258398A1 (en) 2009-05-26 2009-05-26 Albumin-amyloid peptide conjugates and uses thereof
PCT/EP2010/057235 WO2010136487A1 (en) 2009-05-26 2010-05-26 Albumin-amyloid peptide conjugates and uses thereof

Publications (1)

Publication Number Publication Date
HK1164168A1 true HK1164168A1 (zh) 2012-09-21

Family

ID=41022577

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105162.7A HK1164168A1 (zh) 2009-05-26 2012-05-25 白蛋白-澱粉樣肽的共軛物和其用途

Country Status (20)

Country Link
US (2) US9023991B2 (zh)
EP (2) EP2258398A1 (zh)
JP (2) JP5936539B2 (zh)
KR (1) KR101459080B1 (zh)
CN (1) CN102458478B (zh)
AR (1) AR076892A1 (zh)
AU (1) AU2010251961B2 (zh)
BR (1) BRPI1011314A2 (zh)
CA (1) CA2763569C (zh)
DK (1) DK2435093T3 (zh)
ES (1) ES2587962T3 (zh)
HK (1) HK1164168A1 (zh)
HU (1) HUE030218T2 (zh)
IL (1) IL216626A (zh)
MX (1) MX2011012677A (zh)
PL (1) PL2435093T3 (zh)
PT (1) PT2435093T (zh)
RU (1) RU2533806C2 (zh)
TW (1) TWI524900B (zh)
WO (1) WO2010136487A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
CN103450347A (zh) * 2012-05-29 2013-12-18 四川百利药业有限责任公司 一种用于治疗阿尔兹海默症的多肽及基因疫苗
CN105315361A (zh) * 2014-07-29 2016-02-10 天津大学 一种酸化白蛋白及制备方法和在抑制β-淀粉样蛋白聚集的应用
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN115715809A (zh) * 2022-11-24 2023-02-28 武汉禾元生物科技股份有限公司 重组人血清白蛋白-药物偶联物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
DE60114157T2 (de) 2000-02-21 2006-06-29 Pharmexa A/S Verfahren zur herabregulierung von amyloid
EP1278544A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
MY144231A (en) * 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
RU2006120077A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Аналоги глюкагоноподобного пептида-1 (glp-1), связанные с альбуминоподобными агентами
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
WO2006107617A2 (en) 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ES2393492T3 (es) 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
ATE535252T1 (de) * 2005-05-05 2011-12-15 Merck Sharp & Dohme Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
CA2607056C (en) 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
TR201802286T4 (tr) * 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Peptidle bağışıklık yanıtının arttırılması için yöntem.

Also Published As

Publication number Publication date
TW201109033A (en) 2011-03-16
JP5936539B2 (ja) 2016-06-22
IL216626A0 (en) 2012-02-29
IL216626A (en) 2016-10-31
EP2258398A1 (en) 2010-12-08
DK2435093T3 (en) 2016-08-15
RU2533806C2 (ru) 2014-11-20
JP2012528111A (ja) 2012-11-12
AR076892A1 (es) 2011-07-13
CA2763569A1 (en) 2010-12-02
EP2435093B1 (en) 2016-06-29
BRPI1011314A2 (pt) 2016-03-15
US9023991B2 (en) 2015-05-05
CA2763569C (en) 2014-10-28
US9163062B2 (en) 2015-10-20
TWI524900B (zh) 2016-03-11
MX2011012677A (es) 2011-12-16
EP2435093A1 (en) 2012-04-04
ES2587962T3 (es) 2016-10-27
RU2011153023A (ru) 2013-07-10
JP5985589B2 (ja) 2016-09-06
PT2435093T (pt) 2016-08-08
KR101459080B1 (ko) 2014-11-07
CN102458478B (zh) 2014-03-19
PL2435093T3 (pl) 2016-11-30
JP2015096512A (ja) 2015-05-21
AU2010251961A1 (en) 2011-12-22
KR20120052906A (ko) 2012-05-24
WO2010136487A1 (en) 2010-12-02
CN102458478A (zh) 2012-05-16
US20140086945A1 (en) 2014-03-27
US20120130049A1 (en) 2012-05-24
AU2010251961B2 (en) 2013-11-28
HUE030218T2 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
HK1250042A1 (zh) 溶酶體靶向肽及其應用
HRP20181493T1 (hr) Konjugati epsilon-polilizin i njihova primjena
SG2014012918A (en) Albumin variants and conjugates
ZA201109324B (en) Multimeric peptide conjugates and uses thereof
ZA201104497B (en) Peptide therapeutic conjugates and uses thereof
IL221278A0 (en) Chlorotoxin polypeptides and conjugates and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
EP2383283A4 (en) NOGGIN PEPTIDE AND ITS USE
GB0916576D0 (en) Polypeptides and uses thereof
EP2474555A4 (en) PEPTIDE DERIVED FROM WNT10 AND USE THEREOF
GB0712670D0 (en) Isolated peptides and uses thereof
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
IL232394A0 (en) Peptides and epitopes against p2x7
EP2513137A4 (en) PEPTIDES DERIVED FROM SAPOSINE-A AND USES THEREOF
HK1164168A1 (zh) 白蛋白-澱粉樣肽的共軛物和其用途
HK1168363A1 (zh) 新型肽及其應用
EP2285827A4 (en) PEPTIDES AND ITS USE
GB0818065D0 (en) Immunogenic peptides and uses thereof
EP2408808A4 (en) TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
EP2450374A4 (en) PEPTIDE AND ITS USE
GB0922384D0 (en) 68GA-labled human serum albumin
GB0903746D0 (en) Novel conjugated proteins and peptides
GB0816561D0 (en) Peptides and uses thereof
GB0800502D0 (en) Peptides and their uses
GB0710813D0 (en) Peptides and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210528